Choi’s next generation CAR-T therapy, funded in part by SAA-Boston and SAA-Nantucket, has shown “dramatic and rapid” regression of glioblastoma
With early funding from Swim Across America – Boston and Swim Across America – Nantucket, Dr. Bryan Choi’s research on tandem CAR T-cell therapy for ependymoma was approved for a Phase I trial. The first human patient was infused at the end of April 2023. The results of the first human trials, as described in 2024 by the New England Journal of Medicine, showed “dramatic and rapid” regression of glioblastoma.
In an exclusive briefing to Swim Across America participants, Dr. Bryan Choi, a neurosurgeon and neuro-oncologist at Massachusetts General Cancer Center, delivered an update on his research path.
From left, brain tumors, marked by red and green arrows, disappear a day after CAR-T immunotherapy treatment. From CNN.
The Swim Across America lab visit included not only highlights from on the ongoing Phase I trial, but also a few first-hand stories about the life-changing impacts of the new CAR-T cell therapy for one of the patients, who has chosen to share his story publicly.
Tom Fraser (Patient #2) has shared his story publicly with news outlets that include CNN and New York Magazine.
Tom Fraser, 72, (center, in the blue shirt) was treated with a single infusion of CAR-T cells. Two days later, an MRI showed a decrease in the tumor’s size by 18.5 percent. By day 69, the tumor had decreased by 60.7 percent, and the response was sustained for over 6 months. From The Harvard Gazette.
CAR T-cell therapy, a type of gene therapy that engineers a patient’s own T-cells (a type of white blood cells) to identify and attack cancer cells by way of their antigen markers, has shown promise in the treatment of blood cancers. The research team created dual antigen-targeting tandem CAR T (TanCART) cells to target heterogeneous solid tumors. Dr. Choi’s research shows that this type of therapy can also be manipulated to treat solid tumors like ependymoma.
At the suggestion of Dr. Howard Weinstein, Unit Chief of Pediatric Hematology/Oncology at Mass General for Children and long-time Swim Across America partner, Dr. Choi applied for a Swim Across America research grant through the internal competitive bid program at Mass General for Children.
Dr. Choi recruiting the next generation of researchers, like SAA – Nantucket supporter, Braden Hussey.
Without the Swim Across America grant, Dr. Choi said, his research likely would have remained unfunded, and neither the FDA approval nor the Phase I Study approval, which is funded by industry investors, would have been possible.
Janel Jorgensen McArdle, Chief Operating Officer of Swim Across America, pointed out that Dr. Choi’s research falls in the “sweet spot” of the high risk, high reward research that Swim Across America is pursuing.
“This promising research aligned perfectly with the opportunities that Swim Across America seeks to support,” said McArdle. “We are so excited that SAA funding could help accelerate it to patient trials – and are thrilled to see the benefits to patients!”
Dr. Choi explained CAR-T cell therapy to the Swim Across America group on April 4, 2025.
After his highly informative presentation, Dr. Choi gave the Swim Across America group a private tour of his lab spaces, which were in the finishing stages of build-out when they toured two years ago.
The group also got to visit the Ether Dome at Mass General, the surgical amphitheater where, in 1846, the first public surgery with anesthesia was performed.
It was an exciting visit for Swim Across America news and for all of the Swim Across America – Boston and Nantucket supporters who were present!
Swim Across America lab visit participants, pictured with Dr. Choi in the Ether Dome at Mass General, site of the first use of anesthesia in public surgery.
Revolutionary CRISPR Gene Editing and Other Cell and Gene Therapy Editing Takes Center Stage in Finding Ways to Effectively Treat Cancer
Swim Across America, the nonprofit funding innovative clinical trials and patient-centered programs for cancer,is proud to announce the award of two $450,000 grants to two of its beneficiaries, Alliance for Cancer Gene Therapy(ACGT) and Dana-Farber Cancer Institute, to support the work of novel gene and base editing techniques used in advanced cancer research, including targeted therapies, immunotherapies and cellular therapies. The two-year grants will specifically support the work of scientific investigators Joseph Fraietta, PhD, at the University of Pennsylvania through ACGT, and Pietro Genovese, PhD, at Dana-Farber Cancer Institute, for their work in groundbreaking cell and gene therapy cancer research. This financial support paves the way for more effective therapies across many cancer types including solid tumors, offering potential new hope for patients with hard to treat cancer types or limited treatment options.
“Gene editing, including CRISPR, are some of the most promising frontiers in cancer research allowing for advances in targeted therapies, immunotherapies, CAR-T cell therapy and early/minimal residual disease detection, diagnostics and cancer vaccines,” said Rob Butcher, CEO of Swim Across America. “These grants to Dr. Fraietta through ACGT, and Dr. Genovese at Dana-Farber, will help accelerate the advancement of potential gene-edited cancer treatments that could transform how we treat patients and their quality of life. Just as our previous funding has helped develop immunotherapy treatments that are saving lives today, we believe these pointed investments will help accelerate the next generation of cancer breakthroughs.”
Joseph Fraietta, PhD
Joseph Fraietta, PhD, through Swim Across America–Fairfield County beneficiary Alliance for Cancer Gene Therapy, is developing an innovative “off-the-shelf” cell therapy for aggressive cancers. His research uses a precise gene-editing tool called a “base editor” to create more effective CAR T cells that can target cancers with KRAS mutations, found in 20-25% of all cancers including lung, colon and pancreatic cancer. His team is also developing “micropharmacies” – immune cells engineered to release powerful cancer-fighting signals directly at tumor sites while minimizing side effects.
Pietro Genovese, PhD
Pietro Genovese, PhD, at Dana-Farber, is taking a revolutionary approach to treating acute myeloid leukemia (AML). Rather than targeting cancer cells directly, his team is creating “stealth” healthy blood cells engineered to survive cancer treatments while allowing the selective elimination of cancer cells. This innovative strategy could provide less toxic treatment options for AML and other blood cancers where traditional therapies often harm healthy cells along with cancerous ones.
“With the current funding landscape and resources potentially constrained, nonprofit organizations play a vital role in ensuring innovative cancer research moves forward,” said Evan Vosburgh, MD, Research and Grants committee chair for Swim Across America. “These targeted grants support precisely the kind of high-risk, high-reward research that could revolutionize cancer treatment, but might otherwise go unfunded. By supporting early-stage research in cell and gene therapy, we’re helping bridge critical funding gaps and accelerating the development of potentially life-saving treatments.”
Swim Across America has raised more than $100 million for cancer research since its founding in 1987 and has a strong track record of funding transformative research, including clinical trials that led to FDA-approved immunotherapy medicines Keytruda, Opdivo, Yervoy and Tecentriq. The organization was also a grant funder of Memorial Sloan Kettering’s landmark clinical trial that achieved a 100% success rate treating advanced rectal cancer patients with dostarlimab.
About Swim Across America Swim Across America hosts open water and pool swims in numerous communities nationwide, from Nantucket to under San Francisco’s Golden Gate Bridge. More than 150 Olympians support the organization, including Michael Phelps, Kate Douglass, Missy Franklin and Ryan Lochte. The organization supports more than 60 cancer research projects annually and has ten named Swim Across America Labs at major institutions nationwide. To learn more visit swimacrossamerica.org or follow on social media @SwimAcrossAmerica on Facebook and @SAASwim on Instagram.
Francesca “Frankie” Grieco-Routh is a kind and caring 13-year-old who loves making art, reading, listening to music, and cheering on her two younger sisters, Emmersan and Augustine. She’s also a leukemia survivor celebrating 10 years of being minimal residual disease (MRD) negative—meaning no cancer cells can be detected in her blood.
“Frankie is so full of life, and her personality is most like Buddy from the movie Elf. She’s full of joy and laughter and wants everyone around her to be happy and comforted,” shared her mother, Giselle. “She loves painting, spending time with family, and being with her service dog, Luna. She’s our warrior.”
This year, the Grieco-Routh family will attend Swim Across America – Tampa Bay on May 10, supported by Emmersan’s team, Team BEST. Emmersan, or Emmie, is an 11-year-old competitive swimmer with St. Petersburg Aquatics and will be a rookie swimmer at this year’s event. She will be joined by friends and teammates to honor her sister Frankie.
The Grieco-Routh family
“Whatever we do, we do it as a family, and we go all in,” said Giselle. “So when Coach Brackin met Emmie and heard our family’s story, she graciously offered to have their team fundraise in Frankie’s honor. Emmie is excited to swim, and doing it for her sister makes it even more special.”
Giselle and her husband, Ryan, moved Frankie, Emmie, and Augustine (August) from Southern California to St. Petersburg, Florida, to be closer to family and ensure Frankie could continue her long-term maintenance care at Johns Hopkins All Children’s Hospital (JHACH). Swim Across America – Tampa Bay raises funds for immunotherapy research at JHACH and has contributed over $2 million to its beneficiaries since 2012.
“The support we’ve received since moving to St. Petersburg has been incredible—not just from the swimming community, but from the amazing team at JHACH. The care Frankie has received there is unmatched,” said Giselle.
Frankie was just three years old when she was diagnosed with leukemia. After months of unexplained illness and several misdiagnoses, Giselle pushed doctors to order a complete series of tests. That’s when they received the devastating news no family wants to hear.
Frankie saw her first movie at the hospital theater while receiving treatment for leukemia.
“The doctor called me and told me to get Frankie to the hospital immediately. Her white blood cell count was extremely high and her body was shutting down. She was rushed into treatment and spent two weeks in the hospital, receiving intense chemotherapy daily and undergoing countless procedures, including weekly spinal taps,” said Giselle.
At the time, Giselle and Ryan had Frankie, 10-month old Emmie, and just found out she was pregnant with their third daughter.
“To say it was overwhelming would be an understatement!” joked Giselle.
Despite everything, Frankie amazed everyone with her strength. Because her immune system was severely compromised, she couldn’t leave her hospital room, but that didn’t stop her from keeping herself entertained with art and movies.
“She would even make art out of her food—stacking bagels and spreading jelly on trays! She was so strong despite being in so much pain,” Giselle shared.
Frankie’s strength extended beyond her own battle—she found ways to comfort other families fighting similar struggles. Even if she couldn’t leave her room, she still sent love and support from afar.
“Every time we heard another family having a tough time—a child crying or a mother sobbing through a broken heart—we’d send them love through our ‘magic fingers,’” Giselle said, as she and Frankie wiggled their fingers in the air.
August, Emmie and Frankie Grieco-Routh
As Emmie takes on open water swimming with her team, Frankie, Giselle, Ryan, and August will be on the beach cheering her on. No matter the challenge, they face it together.
“Whether it’s swimming, gymnastics, or leukemia, we are each other’s biggest cheerleaders and support system. Seeing our daughters support each other through thick and thin makes us incredibly proud.”
If you are inspired to support Frankie, Emmie and Team BEST, give here.
When Sarah Wiseman was diagnosed with breast cancer in June 2022, it came as a complete shock. Though her mother had been diagnosed with the same cancer in her 60s, Sarah’s genetic marker testing had come back negative. It was a routine mammogram that led to her breast cancer diagnosis.
“I had a routine mammogram that was concerning, which led to further diagnostic testing—an ultrasound and a biopsy,” Sarah explained.
“I had a seed inserted via biopsy, then underwent a partial mastectomy/lumpectomy and lymph node removal during surgery. One lymph node tested positive for metastasis. After healing from surgery, I received radiation treatment on my lymph nodes and left breast — 20 treatments in total. I’m grateful to have had access to a tumor test that evaluated the effectiveness of chemotherapy on my specific tumor. The results came back below the threshold for needing chemo!”
Sarah Wiseman, a member of the SAA-Nashville committee, was declared in remission from breast cancer in 2023.
This year, Sarah celebrates her remission and looks forward to swimming in the 4th Annual Swim Across America – Nashville. Funds raised from the event support Vanderbilt-Ingram Cancer Center (VICC), where Sarah received treatment.
Sarah swam as a child but really fell into the sport watching her children swim on club teams and in college. Once she got the all-clear from her doctors, Sarah knew exactly how to get her strength back while doing something she loved.
“After I healed from my surgeries, I couldn’t wait to swim. I joined the local Masters team, and thanks to my friend Chris McPherson, I was introduced to Swim Across America,” said Sarah.
Chris McPherson, along with Alyssa Corb and Laurin Bobo, is a co-event director for SAA-Nashville.
“This community event is a wonderful way for me to give back to the doctors, nurses, and caregivers who took such great care of me during treatment,” Sarah said.
Swim Across America’s guiding principle is that money raised locally stays local — something that resonated deeply with Sarah. She takes great pride in supporting an organization that directly benefits her community, especially given her firsthand experience with how much cancer treatment has evolved.
Members of the SAA-Nashville committee and researchers from Vanderbilt-Ingram Cancer Center present the fundraising total at the 2024 SAA-Nashville community pool swim.
“In the past, having a positive lymph node would have meant automatic chemotherapy. Today, I am closely monitored by my medical oncologist and surgical oncologist at Vanderbilt Breast Center. And I’m proud to be raising funds for others in our community—people who will be treated at VICC, just like I was,” said Sarah. “I am a beneficiary of the incredible advances in cancer treatment. My mother didn’t have access to these options during her fight. She really struggled, and I believe newer-generation treatments made my journey much easier.”
Now in remission, Sarah is grateful that Swim Across America allows her to support two of her greatest passions: swimming and the cancer care team at VICC.
“I just feel incredibly blessed to have received the life-saving treatment I did,” Sarah shared. “Swimming has had the best impact on my health, and since my cancer diagnosis, I’ve embraced a much healthier lifestyle. I love that SAA allows me to give back through two of my favorite things: swimming and Vanderbilt-Ingram Cancer Center.”
If you’re inspired to support Sarah and team Wisemans Wack Cancer, give here.
For 15 years, Swim Across America has fueled innovative early-stage research at Fred Hutch Cancer Center and UW Medicine and helped launch the careers of dozens of young scientists. We’re proud to share details about the six most recent projects made possible through funds raised in 2022 and 2023 by Swim Across America – Seattle and the dedicated swimmers who participated. From improving patients’ quality of life to overcoming tumors’ resistance to immunotherapy, these innovative projects have the potential to dramatically enhance cancer treatment.
Inspired to Make Waves to Fight Cancer this year? Swim, volunteer or donate to SAA-Seattle at swimacrossamerica.org/seattle.
Kate Markey, MBBS, PhD, FRACP | Stem cell transplantation
Assistant Professor, Fred Hutch and UW Medicine
Project: Restoring the gut microbiome after blood stem cell transplant
Dr. Kate Markey
Background: Fred Hutch researchers have shown that while blood stem cell transplantation continues to be the most effective treatment for multiple myeloma, it can also severely damage patients’ gut microbiome, leading to strong gastrointestinal side effects and poor outcomes. Dr. Markey, a medical oncologist who studies the gut microbiome and its role in recovery from transplant, developed a study to examine whether a five-week, plant based, whole-food diet can restore patients’ beneficial gut bacteria and improve immune function and outcomes.
2024 progress statement: Dr. Markey and her colleagues opened the trial in October, and by the end of the following month they had enrolled seven patients, or one-third of their goal. They are collecting stool and blood samples and plan to analyze all of them once the trial is complete. If all goes as expected this summer they intend to use the resulting data to apply for a federal research grant to support a much larger, randomized clinical trial.
Alexandre Hirayama, MD | Blood cancers
Assistant Professor, Fred Hutch and UW Medicine
Project: Understanding how large B-cell lymphoma evades CAR T-cell therapy
Dr. Alexandre Hirayama
Background: Less than half of patients who undergo CAR T-cell therapy for large B-cell lymphoma (LBCL) enjoy long-lasting remission. We’re not sure why, but the answer may lie in the tumor microenvironment. There’s still so much we don’t know about this collection of cells, stroma, and blood vessels that surround and support the tumor, including how it might suppress cancer therapies. Dr. Hirayama, who specializes in treating patients with B-cell malignancies, is studying the tumor microenvironment in minute detail to help identify and explain how patients’ tumors may mute CAR T cells’ effectiveness.
2024 progress statement: Dr. Hirayama has gathered the necessary tumor samples for these studies and refined the techniques and technologies that will allow him to study immune, stromal, and tumor cells in the tumor microenvironment. He expects to begin studying the samples in summer 2025.
Diane Tseng, MD, PhD | Lung cancer
Assistant Professor, Fred Hutch and UW Medicine
Project: Reducing inflammatory effects of immunotherapy in patients with lung cancer
Dr. Diane Tseng
Background: Many patients with lung cancer who are treated with checkpoint inhibitors experience a condition called checkpoint inhibitor pneumonitis (CIP). If left untreated, CIP can cause irreversible damage. Recent research shows that immune cells called napsin A–specific T cells may be involved in mediating CIP. Dr. Tseng, an oncologist who specializes in treating patients with lung cancer, is working with McGarry Houghton, MD — a Fred Hutch and UW Medicine professor and holder of the Satya and Rao Remala Family Endowed Chair — to study napsin A–specific T cells’ role in CIP and exploring strategies for muting it.
2024 progress statement: Dr. Tseng’s work has focused on 1) developing a method for detecting napsin A– specific T cells in donor blood; 2) developing a method for taking those cells and growing more of them in the lab; and 3) creating a test to determine whether a different T cell can eliminate them. This work will establish the foundations for understanding the function of napsin A–specific T cells and the role they might play in CIP.
Emily Liang, MD | Blood cancers
Hematology/oncology Fellow, Fred Hutch and UW Medicine
Project: Mitigating serious side effects of CAR T-cell therapies in patients with blood cancers
Dr. Emily Liang
Background: While CAR T-cell therapy has revolutionized treatment for patients with blood cancers like lymphoma and multiple myeloma, it also comes with a high risk of fever, fatigue, body aches, and even neurologic impairment. Though these conditions are reversible, they can be life-threatening and prevent older and frailer patients from receiving CAR T-cell therapy at all. Dr. Liang, who specializes in acute leukemias and CAR T-cell therapy, and her mentor, Jordan Gauthier, MD, MSC, a Fred Hutch and UW professor and former Swim Across America funding recipient, want to make these treatments accessible to a wider range of patients. So, the pair launched a first of-its-kind trial to study whether a drug typically prescribed for rheumatoid arthritis called anakinra can prevent these inflammatory responses.
2024 progress statement: After treating more than 30 patients in their clinical trial, Drs. Liang and Gauthier found that prophylactic administration of anakinra did not seem to be effective in preventing cytokine release syndrome, a side effect associated with a high level of inflammation in the blood. However, prophylactic anakinra did seem to reduce the severity and duration of neurologic side effects as well as the need for steroids. Importantly, Drs. Liang and Gauthier also found that anakinra may impair the treatment’s effectiveness against tumors. Now, the pair are planning to study how anakinra mitigates inflammation in the brain, whether there may be alternative prevention strategies, and how anakinra impacts CAR T-cell function.
Saurav Kumar, PhD | Colorectal cancer
Postdoctoral Fellow, Fred Hutch
Project: Exploring new uses for existing drugs to treat colorectal cancer
Dr. Saurav Kumar
Background: Colorectal cancer is one of several cancers driven by a process called gene fusion, in which two independent genes combine incorrectly and begin producing proteins that can lead to cancer. And though a range of drugs have been developed to target these fusions and stop the mechanism that promotes cancer growth, they’ve so far been ineffective against colorectal cancer. However, Dr. Kumar, who studies metastasis, recently discovered that patients with colon cancer who receive TRK inhibitors (TRKi) experience a drop in TRK fusion protein levels, suggesting that these inhibitors may be degrading the cancer-causing fusion proteins. He plans to study the interaction that causes this protein degradation with the goal of one day using TRKi to create more effective therapies for patients with this form of cancer.
2024 progress update: Dr. Kumar and his colleagues have developed three protein degraders, called PROTACs, based on an FDA-approved TRKi. Now they plan to begin testing them on colorectal cancer cells in the lab to better understand the mechanism that leads to TRK fusion protein degradation — which could one day inform the development of targeted therapies for patients with these cancers.
Yapeng Su, PhD | Pancreatic cancer
Postdoctoral Fellow, Fred Hutch
Project: Overcoming solid tumors’ resistance to immunotherapies
Dr. Yapeng Su
Background: Pancreatic cancer is notoriously difficult to treat. Though we’ve found a protein on tumor cells that would seemingly make for a good immunotherapy target, treatments that have been studied and validated in the lab fail in patients — likely due to unique characteristics of the tumor microenvironment. Using technology that allows us to see the interaction of cells within tumors and better understand how they influence one another, Dr. Su, who studies adoptive cellular immunotherapy, is examining the mechanisms that cause immunotherapies to fail and exploring techniques to overcome them.
2024 progress statement: After completing a detailed study of samples from tumors previously treated with adoptive T cell therapy, Dr. Su found that they contained several cell types that were both potentially immunosuppressive and arranged in distinct patterns throughout the tumor microenvironment. He also identified several subtypes of T cells (whose role is to attack cancer cells) that no longer functioned properly. In the coming months, Dr. Su plans to further analyze the T-cell subtypes and their placement within the tumor microenvironment to better understand why they stop working. What he finds could one day help us better engineer T cells to overcome those immunosuppressive forces.
Swim Across America (SAA) is pleased to announce the winners of the 2024 SAA College Cup. More than 45 collegiate, club, and alumni teams and over 1,400 participants all united to make waves in the fight against cancer through swimming and friendly competition.
Swim Across America awarded the top fundraising team, the top collegiate fundraiser, and a bonus team chosen at random.
Congrats to the top fundraising team, Team Tar Heel! The top team is led by co-captains, Georgia Nel and Sue Walsh, and raised more than $96,000. Funds raised by Team Tar Heel supported the Swim Across America – Carolina community.
Team Tar Heel from the SAA-Carolina community is the winner of the Swim Across America College Cup. Congrats!
For Olympian and University of North Carolina at Chapel Hill alum, Sue Walsh, Swim Across America’s mission is deeply personal.
“My involvement became even more personal when I heard the words myself, ‘You have metastatic colon cancer.’ As someone who spent most of her life committed to the sport of swimming, it made perfect sense to partner with SAA in the fight against cancer, including my own.”
Congrats to the top collegiate fundraiser, Alyssa Corb, who raised over $24,000! Alyssa is a student at the University of Tennessee, Swim Across America – Nashville co-event director, and long-time supporter of Swim Across America – Baltimore. Over the years, Alyssa and her family have raised more than $200,000.
Alyssa Corb and her mother, Jennifer, at the 2024 SAA-Nashville community swim.
“My main inspiration for swimming is my brother Michael, who passed away from mixed lineage leukemia when he was nine months old,” shared Alyssa.
“I was 2 when he was born and 3 when he was diagnosed and died. I don’t remember every second but I do remember loving every minute with him, and his face lighting up whenever I walked into his room. To me, Swim Across America is not just about raising money to find a cure, it’s to honor and remember those who fought their battle and prevent other parents, siblings, and families from going through the loss of a loved one.”
SAA also recognized a collegiate team chosen through a random drawing: Providence College Swimming and Diving team from Providence Rhode Island. The team of more than 100 swimmers raised more than $64,000 and were awarded a Vasa Trainer Pro. Funds raised by the team from Providence College Swimming and Diving supported Swim Across America – Rhode Island.
The Swim Across America College Cup was announced in 2023 and invited college teams, athletes, and alumni to join the organization’s mission of funding cancer research, clinical trials, and patient care programs through community charity swims. Teams participated by registering for one of Swim Across America’s open water charity swims, joining or starting a pool swim, or participating virtually through the SAA My Way program. Participants affiliated with a U.S-based college or university were eligible to compete in the College Cup. Teams consisted of current college students, alumni, or a mix of both, and could be small as one person.
The Swim Across America College Cup was supported through partnerships with CSCAA, Vasa, and GoSwim.
About Swim Across America
Swim Across America, Inc. (SAA) is dedicated to raising money and awareness for cancer research, prevention, and treatment through swimming-related events. With the help of hundreds of volunteers nationwide and past and current Olympians, Swim Across America is helping find a cure for cancer through athleticism, community outreach and direct service. To learn more visit swimacrossamerica.org or follow on Facebook @SwimAcrossAmerica or on Instagram @SAASwim.
About CSCAA
Founded in 1922, the CSCAA is the nation’s first professional coaching association for intercollegiate athletics. The CSCAA boasts more than 2,000 member coaches and assistant coaches, recognizes All-American swimmers and divers, NCAA record-breakers and Scholar All-America athletes and teams, as well as outstanding coaches and contributors, and helps oversee the welfare of collegiate swimming and diving. Learn more about CSCAA at cscaa.org.
About Vasa
Vasa empowers swimmers, surfers, and triathletes to become stronger, better, faster in sports, fitness, and injury rehab. Vasa offers specific equipment such as swim ergometers, trainers, sport benches and other accessories to provide athletes with safe, effective training methods. Founded by Rob Sleamaker, an acclaimed exercise physiologist and author, who has worked with Olympians, biathletes, and triathletes as well as some of the world’s most respected swim coaches to reinvent their training practices. Learn more about Vasa at vasatrainer.com.
About GoSwim
GoSwim creates content that helps people of all ages and backgrounds to swim better and reach their full potential in the sport. GoSwim’s videos are acclaimed and unsurpassed for clarity of filming and clarity of content and commentary. GoSwim was founded in 2002 by Olympian Glenn Mills and business colleague Barbara Hummel. Learn more at goswim.tv.
Congratulations to Swim Across America President and CEO, Rob Butcher, for receiving the prestigious Richard Steadman Award from the College Swimming Coaches Association of America (CSCAA).
This recognition honors his exceptional leadership, dedication, and contributions to the swimming community and the fight against cancer with Swim Across America.
As the President and CEO of Swim Across America since 2016, Butcher has guided the organization through tremendous growth and success. Under his leadership, Swim Across America has continued to expand its reach, with events across the country raising millions of dollars annually to support cancer research and treatment. His passion for SAA’s mission is deeply personal: both his grandmother and stepmother were cancer survivors, and his mother, whom he calls his hero, lost her battle with appendix cancer in 2007.
Before joining SAA, Butcher served as Executive Director for U.S. Masters Swimming (USMS) for seven years. During his tenure, he transformed USMS into a professionally managed organization, developing the creation of the Masters Coach Certification and Adult Learn-to-Swim programs. Under his leadership, membership grew by more than 50%, and revenue tripled to $3.6 million.
A Georgia Southern University graduate and competitor in the 2000 U.S. Olympic Trials, Butcher has demonstrated a lifelong commitment to the sport of swimming.
His leadership at SAA has been instrumental in expanding its impact, with the organization raising over $100 million for cancer research since its inception in 1987.
“Rob Butcher exemplifies the very spirit of the Steadman Award—leadership, integrity, and an unwavering commitment to serving others,” said Samantha Barany, Executive Director of the CSCAA. “Through the water, he fights cancer every day, and we are all better off for his dedication to making a difference. Rob has profoundly impacted the swimming community and every community where Swim Across America has a presence. His passion for people and his ability to spread happiness wherever he goes are truly inspiring.”
Rob Butcher resides in Charlotte, North Carolina, with his wife Allison and their twin boys. He remains an active advocate for cancer research and a unifying force within the swimming community. His receipt of the Richard Steadman Award highlights not only his professional achievements but also his heartfelt commitment to making a lasting impact in the fight against cancer. For more information about Swim Across America and its mission, visit swimacrossamerica.org.
Swim Across America 